• İlknur Deliktaş Onur, Tuğba Başoğlu, Nazım Can Demircan, Tuğba Akin Telli, Rukiye Arikan, Özlem Ercelep, Nazım Serdar Turhal, Mehmet Akif Öztürk, Perran Fulden Yumuk, and Faysal Dane.
• Division of Oncology, Department of Internal Medicine, University of Health Sciences, Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital, Ankara, Turkiye.
• Turk J Med Sci. 2024 Jan 1; 54 (6): 120512141205-1214.

Background/AimThe Memorial Sloan Kettering Cancer Center (MSKCC) nomogram was developed to predict survivorship in gastric cancer patients undergoing R0 resection. This study aimed to evaluate the predictive power of this nomogram in the Turkish patient population.Materials And MethodsGastric cancer patients over 18 years of age who were admitted to our clinic between 2000 and 2019 and underwent primary curative surgery and R0 resection were included in the study. The 5- and 9-year overall survival (OS) rates of 489 patients were analyzed. Real-life survival rates and those calculated using the MSKCC tool were compared in all the patients and subgroups. The relationship between the variables and survival were analyzed.ResultsThe 5-year median observed OS rate for all the patients was 51.7%, while the 5-year median OS rate calculated using the MSKCC tool was 48.5%. The difference between the expected and observed survival rates was 3.2%. The rates were similar and there was no statistically significant difference (p = 0.31). The 9-year median observed OS rate for all the patients was 41.4%, while the 5-year median OS rate calculated using the MSKCC tool was 41%. The difference between the expected and observed survival rates was 0.4%. The rates were similar and there was no statistically significant difference (p = 0.9).ConclusionThe 5- and 9-year survival rates estimated using the MSKCC tool were correlated with the 5- and 9-year survival rates in the real-life data. Hence, the use of the MSKCC prognostic tool in clinical practice should be expanded.© TÜBİTAK.

21 keywords...

hide…